Certara, Inc. (NASDAQ:CERT) Receives Average Rating of “Hold” from Brokerages

Certara, Inc. (NASDAQ:CERT) has earned a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $15.92.

CERT has been the subject of a number of recent research reports. Robert W. Baird reduced their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Barclays cut their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th.

Certara Trading Up 1.6 %

Shares of Certara stock opened at $14.23 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a twelve month low of $9.41 and a twelve month high of $19.87. The firm has a market capitalization of $2.29 billion, a PE ratio of -71.15, a P/E/G ratio of 9.85 and a beta of 1.52. The firm’s 50-day moving average price is $11.53 and its 200 day moving average price is $11.86.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same period in the previous year, the company posted $0.06 earnings per share. The business’s revenue was up 10.7% on a year-over-year basis. On average, sell-side analysts predict that Certara will post 0.28 EPS for the current fiscal year.

Institutional Trading of Certara

Several hedge funds have recently made changes to their positions in CERT. Brown Brothers Harriman & Co. acquired a new position in Certara in the third quarter valued at approximately $27,292,000. Wasatch Advisors LP raised its position in Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after purchasing an additional 1,651,076 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after purchasing an additional 1,128,006 shares during the last quarter. Glenmede Trust Co. NA grew its holdings in shares of Certara by 78.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock worth $14,123,000 after purchasing an additional 530,598 shares during the period. Finally, Kopion Asset Management LLC acquired a new stake in shares of Certara during the 3rd quarter worth about $4,457,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.